Unlike in breast cancer, where HER2 overexpression is well-established and successfully targeted by therapies like trastuzumab, only rare individual cases of melanoma exhibit HER2 alterations that lead to HER2 overexpression. This evidence concerns the gene ERBB2 and melanoma.